ArticleJournal of viral hepatitis2026
Real-World Impact of a Simplified 'Test and Treat' Strategy for In-Hospital HCV Micro-Elimination.
Article in Journal of viral hepatitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Impact of a Simplified 'Test and Treat' Strategy for In-Hospital HCV Micro-Elimination.Journal of viral hepatitis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Hepatitis C virus (HCV) micro-elimination faces challenges from fragmented care pathways, particularly in high-prevalence regions with complex genotypes and socioeconomic barriers. This study evaluated a simplified 'Test and Treat' (TNT) strategy to enhance in-hospital HCV micro-elimination by reducing delays and improving linkage to care. Outcomes including HCV RNA testing rates, treatment uptake rates, time to treatment initiation and sustained virological response at 12 weeks (SVR12) of Pre-TNT (Jan. 2022-Dec. 2022) and post-TNT (Jan. 2023-Dec. 2024) were compared. Following TNT implementation, among 168,527 screened patients, the HCV RNA testing rate increased to 93.96% (2070/2203) from 68.17% under pre-TNT, and the treatment rate among viremic patients rose to 81.98% (678/827) from 63.05%. The median time to treatment initiation was dramatically reduced from 12.5 to 3.8 days. SVR12 remained high, with a rate of 99.71%. Barriers among untreated patients were investigated via surveys and follow-ups. Surveys of 500 HCV antibody positive patients revealed limited affordability (only 5% could bear costs > ¥8000) and low health literacy (only 39% knew about prevention and treatment). Among 149 untreated viremic patients, financial constraints and the perception that treatment was unnecessary while asymptomatic were key refusal reasons. The in-hospital streamlined TNT strategy significantly improved HCV RNA testing linkage and treatment uptake, markedly reduced time to treatment initiation and achieved near-universal cure, surpassing WHO treatment targets. Its effectiveness supports broader adoption in high-prevalence regions, though complementary interventions addressing affordability and health literacy are needed for further progress.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.